Abstract
Background: 3,4-diaminopyridine (3,4-DAP) is a drug to treat symptoms of Lambert-Eaton myasthenic syndrome (LEMS) but still unapproved in Japan. With approval of Hokkaido University Graduate School of Medicine Ethics Committee and Obihiro Kosei General Hospital Ethics Committee, we have treated LEMS patients with 3,4-DAP since 2004.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
